Personalis (NASDAQ:PSNL) CEO Christopher Hall Sells 100,000 Shares

Personalis, Inc. (NASDAQ:PSNL) CEO Christopher Hall sold 100,000 shares of Personalis stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $15.08, for a total value of $1,508,000.00. Following the sale, the chief executive officer directly owned 235,986 shares in the company, valued at approximately $3,558,668.88. This trade represents a 29.76% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Personalis Price Performance

Shares of PSNL stock opened at $14.65 on Friday. Personalis, Inc. has a 12-month low of $3.84 and a 12-month high of $15.36. The firm has a market capitalization of $1.53 billion, a price-to-earnings ratio of -14.36 and a beta of 2.24. The business has a 50 day simple moving average of $9.81 and a 200 day simple moving average of $8.62.

Personalis (NASDAQ:PSNL) last announced its earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.06). Personalis had a negative net margin of 148.11% and a negative return on equity of 43.52%. The business had revenue of $15.47 million for the quarter, compared to the consensus estimate of $14.48 million. On average, equities analysts anticipate that Personalis, Inc. will post -1.06 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have commented on PSNL shares. Morgan Stanley raised their target price on shares of Personalis from $9.00 to $13.00 and gave the company an “equal weight” rating in a research note on Thursday. Wall Street Zen lowered shares of Personalis from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. BTIG Research dropped their target price on Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Monday, May 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a research report on Tuesday, April 21st. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $11.67.

Institutional Trading of Personalis

A number of hedge funds and other institutional investors have recently made changes to their positions in PSNL. Caitong International Asset Management Co. Ltd boosted its holdings in Personalis by 76.1% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock worth $27,000 after buying an additional 1,479 shares in the last quarter. Deutsche Bank AG increased its holdings in shares of Personalis by 4.5% in the fourth quarter. Deutsche Bank AG now owns 38,827 shares of the company’s stock valued at $309,000 after buying an additional 1,655 shares in the last quarter. Royal Bank of Canada increased its holdings in shares of Personalis by 3.2% in the first quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock valued at $275,000 after buying an additional 2,395 shares in the last quarter. Howland Capital Management LLC lifted its position in shares of Personalis by 0.9% during the 2nd quarter. Howland Capital Management LLC now owns 285,308 shares of the company’s stock valued at $1,872,000 after acquiring an additional 2,500 shares during the last quarter. Finally, Intech Investment Management LLC boosted its stake in shares of Personalis by 23.4% during the 4th quarter. Intech Investment Management LLC now owns 20,342 shares of the company’s stock worth $162,000 after acquiring an additional 3,851 shares in the last quarter. 61.91% of the stock is currently owned by institutional investors.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.